news & events
portfolio news
30.10.19
Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis
17.10.19
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
15.10.19
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting
09.10.19
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia
01.10.19
AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury
11.09.19
CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device
16.07.19
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
26.06.19
Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise
04.06.19
Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation
04.06.19
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
